|
?:authorAffiliation
|
-
[\'GigaGen Inc., South San Francisco, CA, USA.\', \'Department of Molecular, Cell, and Developmental Biology, University of California, Santa Cruz, Santa Cruz, CA, USA.\', \'PHASTAR, Inc., San Diego, CA, USA.\', \'Statens Serum Institut, Copenhagen, Denmark.\', \'Grifols S.A., Sant Cugat del Vallès, Spain.\', \'Immunobiology Section, Great Ormond Street Institute of Child Health, University College London, London, England.\', \'Department of Preclinical Sciences, Faculty of Medical Sciences, The University of the West Indies, St. Augustine Campus, St. Augustine, Trinidad and Tobago.\', \'Vitalant Research Institute, San Francisco, CA, USA.\', \'Chamow & Associates, Inc., San Mateo, CA, USA.\', \'Regional Biocontainment Laboratory, Duke University Medical Center, Durham, NC, USA.\', \'MedPharmics, Inc., Metairie, LA, USA.\', \'Waisman Biomanufacturing, University of Wisconsin, Madison, WI, USA.\', \'Stanford Diabetes Research Center, Stanford University Medical Center, Stanford, CA, USA.\', \'Stanford Cancer Institute, Stanford University Medical Center, Stanford, CA, USA.\', \'GigaGen Inc., South San Francisco, CA, USA. djohnson@gigagen.com.\']
|
![[This page as RDF]](https://research.tib.eu/covid-19/static/rdf-icon.gif){kind=icon}